PetMed Express to Restate Financials Due to PetCareRx Acquisition Errors

TL;DR

**PETS is restating financials due to acquisition accounting errors, watch for potential stock dip.**

AI Summary

PetMed Express, Inc. (PETS) filed an 8-K on February 8, 2024, reporting that it will restate its previously issued financial statements. This restatement is due to an error in accounting for certain non-cash items related to its acquisition of PetCareRx, specifically regarding the amortization of intangible assets and contingent consideration. This matters to investors because financial restatements can signal internal control weaknesses and may lead to a loss of investor confidence, potentially impacting the stock price.

Why It Matters

This restatement could erode investor trust and potentially lead to a decline in PetMed Express's stock price as it signals issues with financial reporting accuracy.

Risk Assessment

Risk Level: medium — Financial restatements, especially those involving acquisitions, often indicate internal control deficiencies and can negatively impact investor confidence and stock valuation.

Analyst Insight

A smart investor would closely monitor the upcoming restated financials and management's explanation for the errors, as well as any potential impact on future earnings guidance, before making investment decisions.

Key Players & Entities

• PetMed Express, Inc. (company) — the registrant filing the 8-K
• PetCareRx (company) — the acquired company whose accounting led to the restatement
• February 7, 2024 (date) — date of earliest event reported
• February 8, 2024 (date) — date the 8-K was filed
• PETS (company) — trading symbol for PetMed Express, Inc.

Forward-Looking Statements

• PetMed Express's stock price (PETS) will experience downward pressure. (PETS) — medium confidence, target: Q1 2024
• The company will provide updated financial statements and further details on the restatement. (PetMed Express, Inc.) — high confidence, target: Q2 2024

FAQ

From the Filing

0001040130-24-000004.txt : 20240208 0001040130-24-000004.hdr.sgml : 20240208 20240208160356 ACCESSION NUMBER: 0001040130-24-000004 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240207 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240208 DATE AS OF CHANGE: 20240208 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PETMED EXPRESS INC CENTRAL INDEX KEY: 0001040130 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 650680967 STATE OF INCORPORATION: FL FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-28827 FILM NUMBER: 24608964 BUSINESS ADDRESS: STREET 1: 420 SOUTH CONGRESS AVENUE CITY: DELRAY BEACH STATE: FL ZIP: 33445 BUSINESS PHONE: (561) 426-4444 MAIL ADDRESS: STREET 1: 420 SOUTH CONGRESS AVENUE CITY: DELRAY BEACH STATE: FL ZIP: 33445 8-K 1 pets-20240207.htm 8-K pets-20240207 0001040130 FALSE 0001040130 2024-02-07 2024-02-07 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):  February 7, 2024 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 420 South Congress Avenue , Delray Beach , Florida 33445 (Address of principal executive offices) (Zip Code) ( 561 )  526-4444 (Registrant’s telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $.001 per share PETS NASDAQ Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 2.02 Results of Operations and Financial Condition. On February 8, 2024, PetMed Express, Inc. (the “Company”) issued a press release announcing selected preliminary unaudited financial results for the fiscal quarter ended December 31, 2023. These preliminary financial results are unaudited, based on currently available information and do not present all necessary information for a complete understanding of the Company’s financial condition as of December 31, 2023 or its results of operations for the quarter ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8